KEYNOTE-630: Phase 3 study of adjuvant pembrolizumab versus placebo in patients with high risk, locally advanced cutaneous squamous cell carcinoma. Geiger, J., Daniels, G. A., Cohen, E. W., Ge, J., Gumuscu, B., Swaby, R. F., Chang, A. S. AMER SOC CLINICAL ONCOLOGY. 2019

View details for DOI 10.1200/JCO.2019.37.15_suppl.TPS9597

View details for Web of Science ID 000487345803476